Digest Network Come funziona
Network
/
Società
De
Non verificato

Delix Therapeutics

Di cosa scriviamo

BiotecnologiaFarmaceuticaMedicina - VariePsichiatriaSalute

4 comunicati stampa

Guarda tutti i comunicati
28/10/2025
Psichiatria
Scienza
Igiene alimentare
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Delix Therapeutics Announces Positive Efficacy Data for DLX-001 (Zalsupindole) and FDA Clearance of Phase II Trial Design Featuring At‑Home Administration
Fonte
Delix Therapeutics
Emittente
Business Wire
1.00
0
16/10/2025
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Industria
Delix Therapeutics Study Demonstrates that the Non‑Hallucinogenic Neuroplastogen Zalsupindole Promotes Neuroplasticity Like Ketamine and Psychedelics
Fonte
Delix Therapeutics
Emittente
Business Wire
1.00
0
12/12/2024
Biotecnologia
Farmaceutica
Sanità
Salute
Igiene alimentare
Psichiatria
Medicina - Varie
Industria
Eventi
Delix Presents Full Results from Phase 1 Trial of DLX-001 at ACNP Annual Meeting
Fonte
Delix Therapeutics
Emittente
Business Wire
1.00
0
04/12/2024
Industria
Psichiatria
Scienza
Medicina - Varie
Biotecnologia
Salute
Farmaceutica
Sanità
Delix Therapeutics Announces Dosing of First Patient in Phase 1b Clinical Trial for DLX-001 in Major Depressive Disorder
Fonte
Delix Therapeutics
Emittente
Business Wire
1.00
0

Recapiti

Social Media

Seguaci
0
Compatibilità
0